{"title":"Mounjaro","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003eMounjaro (tirzepatide) is Eli Lilly’s dual GIP\/GLP-1 receptor agonist, supplied as a pre-filled KwikPen. All presentations are Prescription Only Medicines. It \u003cspan data-teams=\"true\"\u003eis indicated for Weight management, in conjunction with dietary measures and increased physical activity in individuals with a BMI of 30 kg\/m2 or more, or in individuals with a BMI of 27 kg\/m2 or more in the presence of at least one weight-related co-morbidity, and for treatment of Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic drugs.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003eHealthxchange supplies the Mounjaro KwikPen range to verified registered prescribers across the UK and Ireland. Every order is dispensed against a valid prescription, or larger volumes can be supplied without a prescription to eligible clinics and pharmacies.\u003c\/p\u003e","products":[{"product_id":"mounjaro-kwikpen-2-5mg-pre-filled-pen-2-4ml-with-needles-pom","title":"Mounjaro Kwikpen 2.5mg Pre-Filled Pen 2.4ml with needles (POM) ▼","description":"\u003cp\u003eMounjaro(tirzepatide) solution for injection in pre-filled pen Pharmacology: Long-acting dual GIP and GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, lowers glucagon, delays gastric emptying and reduces appetite and energy intake. Licensed indication:\u003c\/p\u003e\n\u003cp\u003eWeight management (weight loss and maintenance) in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg\/m², or ≥27 to \u0026lt;30 kg\/m² with at least one weight-related comorbidity Administration: subcutaneous injection into abdomen or thigh, or upper arm (if a carer injects), rotating sites. Any time of day, with or without food. Missed dose: give within 4 days, otherwise skip. Day may be changed if doses are ≥3 days apart. Warnings and precautions: Acute pancreatitis (stop if suspected; do not restart if confirmed). GI adverse effects and dehydration (risk to renal function). Hypoglycaemia with sulfonylurea or insulin (consider dose reduction). Diabetic retinopathy. Pulmonary aspiration risk under general anaesthesia or deep sedation. Report adverse reactions via the MHRA Yellow Card scheme.\u003c\/p\u003e","brand":"Mounjaro","offers":[{"title":"Default Title","offer_id":49132295684351,"sku":"MOUN25LIL1","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/files\/MOUN25LIL1.jpg?v=1788259613"},{"product_id":"mounjaro-kwikpen-5mg-pre-filled-pen-2-4ml-with-needles-pom","title":"Mounjaro Kwikpen 5mg Pre-Filled Pen 2.4ml with needles (POM) ▼","description":"\u003cp\u003eMounjaro(tirzepatide) solution for injection in pre-filled pen Pharmacology: Long-acting dual GIP and GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, lowers glucagon, delays gastric emptying and reduces appetite and energy intake. Licensed indication:\u003c\/p\u003e\n\u003cp\u003eWeight management (weight loss and maintenance) in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg\/m², or ≥27 to \u0026lt;30 kg\/m² with at least one weight-related comorbidity Administration: subcutaneous injection into abdomen or thigh, or upper arm (if a carer injects), rotating sites. Any time of day, with or without food. Missed dose: give within 4 days, otherwise skip. Day may be changed if doses are ≥3 days apart. Warnings and precautions: Acute pancreatitis (stop if suspected; do not restart if confirmed). GI adverse effects and dehydration (risk to renal function). Hypoglycaemia with sulfonylurea or insulin (consider dose reduction). Diabetic retinopathy. Pulmonary aspiration risk under general anaesthesia or deep sedation. Report adverse reactions via the MHRA Yellow Card scheme.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eStore unopened pens in a refrigerator (2–8 °C). Do not freeze. After first use, may be kept unrefrigerated at no more than 30°C for up to 30 days. Do not use if the solution is cloudy, discoloured or contains particles.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Mounjaro","offers":[{"title":"Default Title","offer_id":49132295749887,"sku":"MOUN5LIL1","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/files\/MOUN5LIL1.jpg?v=1788259616"},{"product_id":"mounjaro-kwikpen-7-5mg-pre-filled-pen-2-4ml-with-needles-pom","title":"Mounjaro Kwikpen 7.5mg Pre-Filled Pen 2.4ml with needles (POM) ▼","description":"\u003cp\u003eMounjaro(tirzepatide) solution for injection in pre-filled pen Pharmacology: Long-acting dual GIP and GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, lowers glucagon, delays gastric emptying and reduces appetite and energy intake. Licensed indication:\u003c\/p\u003e\n\u003cp\u003eWeight management (weight loss and maintenance) in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg\/m², or ≥27 to \u0026lt;30 kg\/m² with at least one weight-related comorbidity Administration: subcutaneous injection into abdomen or thigh, or upper arm (if a carer injects), rotating sites. Any time of day, with or without food. Missed dose: give within 4 days, otherwise skip. Day may be changed if doses are ≥3 days apart. Warnings and precautions: Acute pancreatitis (stop if suspected; do not restart if confirmed). GI adverse effects and dehydration (risk to renal function). Hypoglycaemia with sulfonylurea or insulin (consider dose reduction). Diabetic retinopathy. Pulmonary aspiration risk under general anaesthesia or deep sedation. Report adverse reactions via the MHRA Yellow Card scheme.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eStore unopened pens in a refrigerator (2–8 °C). Do not freeze. After first use, may be kept unrefrigerated at no more than 30°C for up to 30 days. Do not use if the solution is cloudy, discoloured or contains particles.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Mounjaro","offers":[{"title":"Default Title","offer_id":49132295815423,"sku":"MOUN75LIL1","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/files\/MOUN75LIL1.jpg?v=1788259619"},{"product_id":"mounjaro-kwikpen-10mg-pre-filled-pen-2-4ml-with-needles-pom","title":"Mounjaro Kwikpen 10mg Pre-Filled Pen 2.4ml with needles (POM) ▼","description":"\u003cp\u003eMounjaro (tirzepatide) solution for injection in pre-filled pen Pharmacology: Long-acting dual GIP and GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, lowers glucagon, delays gastric emptying and reduces appetite and energy intake. Licensed indication:\u003c\/p\u003e\n\u003cp\u003eWeight management (weight loss and maintenance) in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg\/m², or ≥27 to \u0026lt;30 kg\/m² with at least one weight-related comorbidity Administration: subcutaneous injection into abdomen or thigh, or upper arm (if a carer injects), rotating sites. Any time of day, with or without food. Missed dose: give within 4 days, otherwise skip. Day may be changed if doses are ≥3 days apart. Warnings and precautions: Acute pancreatitis (stop if suspected; do not restart if confirmed). GI adverse effects and dehydration (risk to renal function). Hypoglycaemia with sulfonylurea or insulin (consider dose reduction). Diabetic retinopathy. Pulmonary aspiration risk under general anaesthesia or deep sedation. Report adverse reactions via the MHRA Yellow Card scheme.\u003c\/p\u003e\n\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003cstrong\u003eStore unopened pens in a refrigerator (2–8 °C). Do not freeze. After first use, may be kept unrefrigerated at no more than 30°C for up to 30 days. Do not use if the solution is cloudy, discoloured or contains particles.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Mounjaro","offers":[{"title":"Default Title","offer_id":49132295848191,"sku":"MOUN10LIL1","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/files\/MOUN10LIL1.jpg?v=1788259622"},{"product_id":"mounjaro-kwikpen-12-5mg-pre-filled-pen-2-4ml-with-needles-pom","title":"Mounjaro Kwikpen 12.5mg Pre-Filled Pen 2.4ml with needles (POM) ▼","description":"\u003cp\u003eMounjaro(tirzepatide) solution for injection in pre-filled pen Pharmacology: Long-acting dual GIP and GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, lowers glucagon, delays gastric emptying and reduces appetite and energy intake. Licensed indication:\u003c\/p\u003e\n\u003cp\u003eWeight management (weight loss and maintenance) in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg\/m², or ≥27 to \u0026lt;30 kg\/m² with at least one weight-related comorbidity Administration: subcutaneous injection into abdomen or thigh, or upper arm (if a carer injects), rotating sites. Any time of day, with or without food. Missed dose: give within 4 days, otherwise skip. Day may be changed if doses are ≥3 days apart. Warnings and precautions: Acute pancreatitis (stop if suspected; do not restart if confirmed). GI adverse effects and dehydration (risk to renal function). Hypoglycaemia with sulfonylurea or insulin (consider dose reduction). Diabetic retinopathy. Pulmonary aspiration risk under general anaesthesia or deep sedation. Report adverse reactions via the MHRA Yellow Card scheme.\u003cbr\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eStore unopened pens in a refrigerator (2–8 °C). Do not freeze. After first use, may be kept unrefrigerated at no more than 30°C for up to 30 days. Do not use if the solution is cloudy, discoloured or contains particle\u003c\/strong\u003e\u003cem\u003es.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mounjaro","offers":[{"title":"Default Title","offer_id":49132295880959,"sku":"MOUN125LIL1","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/files\/MOUN125LIL1.jpg?v=1788259626"},{"product_id":"mounjaro-kwikpen-15mg-pre-filled-pen-2-4ml-with-needles-pom","title":"Mounjaro Kwikpen 15mg Pre-Filled Pen 2.4ml with needles (POM) ▼","description":"\u003cp\u003eMounjaro (tirzepatide) solution for injection in pre-filled pen Pharmacology: Long-acting dual GIP and GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, lowers glucagon, delays gastric emptying and reduces appetite and energy intake. Licensed indication:\u003c\/p\u003e\n\u003cp\u003eWeight management (weight loss and maintenance) in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg\/m², or ≥27 to \u0026lt;30 kg\/m² with at least one weight-related comorbidity Administration: subcutaneous injection into abdomen or thigh, or upper arm (if a carer injects), rotating sites. Any time of day, with or without food. Missed dose: give within 4 days, otherwise skip. Day may be changed if doses are ≥3 days apart. Warnings and precautions: Acute pancreatitis (stop if suspected; do not restart if confirmed). GI adverse effects and dehydration (risk to renal function). Hypoglycaemia with sulfonylurea or insulin (consider dose reduction). Diabetic retinopathy. Pulmonary aspiration risk under general anaesthesia or deep sedation. Report adverse reactions via the MHRA Yellow Card scheme.\u003c\/p\u003e\n\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003cstrong\u003eStore unopened pens in a refrigerator (2–8 °C). Do not freeze. After first use, may be kept unrefrigerated at no more than 30°C for up to 30 days. Do not use if the solution is cloudy, discoloured or contains particles.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Mounjaro","offers":[{"title":"Default Title","offer_id":49132295946495,"sku":"MOUN15LIL1","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/files\/MOUN15LIL1.jpg?v=1788259629"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/8841\/7791\/collections\/Mounjaro.jpg?v=1790342890","url":"https:\/\/www.healthxchange.com\/collections\/mounjaro.oembed","provider":"Healthxchange ","version":"1.0","type":"link"}